Clinical trial · Interventional
Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life
Monitoring Physical Function Changes for Patients Living With Pancreatic Ductal Adenocarcinoma: Potential for Better Understanding of Treatment Trajectory and Survival
NCT07255001CI-TRIAL-00098066PanFitrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to measure hand grip strength as part of a clinic visit? * Are changes in hand grip strength related to changes in body composition? * Is hand grip strength related to a person's well-being? * Is hand grip strength related to how a tumour responds to treatment? Participants will squeeze a device with their hand to measure their hand grip strength and complete questionnaires about their well-being when they are seen in clinic for their regular medical care for PDAC.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hand Grip Strength | — | UNRESOLVED | — |
| Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Ductal Adenocarcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hand grip strength assessments using a dynamometer | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Main Study Arm
- description
- The study arm all participants are enrolled into. Participants will complete hand grip strength assessments and questionnaires.
- interventionNames
- Device: Hand grip strength assessments using a dynamometer
Primary outcomes (1)
- measure
- Frequency of Participants with Hand Grip Strength (HGS) Measurements at 6 Months From Treatment Start Date
- timeFrame
- From the date anti-cancer therapy is initiated until the 6-month follow-up assessment.
- description
- The percentage of participants with hand grip strength (HGS) test results at 6 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Secondary outcomes (202)
- measure
- Frequency of Participants with Hand Grip Strength (HGS) Measurements at Study Baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older. * Histological and/or radiological diagnosis of resectable, non-resectable, or metastatic PDAC. For resectable PDAC, adjuvant setting only. * ECOG performance status 0-2. * Life expectancy greater than 6 months as judged by the investigator. * Planned for treatment, either as part of routine care or in combination with an investigational agent within another study. * Ability to hold a dynamometer with one hand. Exclusion Criteria: * Individuals with CT imaging performed outside of Vancouver, BC, Canada. * Individuals who are unfit to undergo CT imaging of the third lumbar vertebra (L3). * Individuals who are currently participating in a structured moderate intensity resistance training program. * Individuals who are otherwise judged by the investigator to be unfit to proceed with this protocol. * Unable to comply with study assessments and follow-up.
References
Publications (35)
- BACKGROUNDArmstrong V, Stretch C, Fitzgerald L, Gopaul A, McKinnon G, Koziak J, Kopciuk K, Brockton N, Bathe O. Characterizing cancer-associated myosteatosis: anatomic distribution and cancer-specific variability of low radiodensity muscle. JCSM Rapid Communications. 2021; 4(2):197-206. doi: 10.1002/rco2.46
- BACKGROUNDSong M, Zhang Q, Tang M, Zhang X, Ruan G, Zhang X, Zhang K, Ge Y, Yang M, Li Q, Li X, Liu X, Li W, Cong M, Wang K, Song C, Shi H. Associations of low hand grip strength with 1 year mortality of cancer cachexia: a multicentre observational study. J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1489-1500. doi: 10.1002/jcsm.12778. Epub 2021 Sep 20. PMID 34545711
- BACKGROUNDCheville A. Rehabilitation of patients with advanced cancer. Cancer. 2001 Aug 15;92(4 Suppl):1039-48. doi: 10.1002/1097-0142(20010815)92:4+3.0.co;2-l. PMID 11519031
- BACKGROUNDAaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365. PMID 8433390
- BACKGROUNDWheelwright S, Darlington AS, Hopkinson JB, Fitzsimmons D, White A, Johnson CD. A systematic review of health-related quality of life instruments in patients with cancer cachexia. Support Care Cancer. 2013 Sep;21(9):2625-36. doi: 10.1007/s00520-013-1881-9. Epub 2013 Jun 25. PMID 23797577
- BACKGROUNDCella D, Stone AA. Health-related quality of life measurement in oncology: advances and opportunities. Am Psychol. 2015 Feb-Mar;70(2):175-85. doi: 10.1037/a0037821. PMID 25730723
- BACKGROUNDHagens ERC, Feenstra ML, van Egmond MA, van Laarhoven HWM, Hulshof MCCM, Boshier PR, Low DE, van Berge Henegouwen MI, Gisbertz SS. Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment. J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):756-767. doi: 10.1002/jcsm.12540. Epub 2020 Feb 25.